BSE Sensex added 98.84 points, or 0.16 per cent, to settle at 61,872.62, while NSE’s Nifty50 jumped 35.75 points, or 0.20 per cent, to end the session at 18,321.15 for the day.

Sensex, Nifty settle higher in volatile trade; AEL & Bajaj Auto rises 3% each; Lincoln Pharma falls 11%

Lincoln Pharmaceuticals records a significant increase in net profit for Q4 and FY23, along with a dividend recommendation, as it continues manufacturing therapeutic products.

Lincoln Pharmaceuticals Reports Strong Profit Growth and Dividend Recommendation

Lincoln Pharma Standalone December 2022 Net Sales at Rs 133.77 crore, up 11.58% Y-o-Y

Lincoln Pharmaceuticals slumped 10.28% to Rs 276.35 after the company reported 12% fall in consolidated net profit to Rs 11.02 crore despite a 29% increase in revenue from operations to Rs 102.58 crore in Q4 FY22 over Q4 FY21.

Lincoln Pharma tumbles after weak Q4 performance

Nandish Shah of HDFC Securities believes that short-term trend of the Nifty is weak. Therefore, his advice is to remain cautious till the Nifty closes above the 17,250 levels.

Hot Stocks | Double-digit Returns From Lincoln Pharma, Globus Spirits, Dalmia Bharat Possible In Short Term. Here’s Why

JMC Projects (India) Ltd, RPSG Ventures Ltd, Lincoln Pharmaceuticals Ltd and Gujarat Fluorochemicals Ltd are among the other gainers in the BSE’s ‘A’ group today, 02 December 2021.

Apex Frozen Foods Ltd leads gainers in ‘A’ group

Lincoln Pharmaceuticals consolidated net profit rises 10.09% in the September 2021 quarter

Eyes Australian market for dermatology, gastro and pain management products

Lincoln Pharma gets Australia’s TGA certification for Gujarat plant

Lincoln Pharmaceuticals on Friday announced that it received approval for the company’s manufacturing facility from Australia’s medicines and medical devices regulator - Therapeutic Goods Administration.

Lincoln Pharma receives approval from Australian Regulator

Company looks to enter the Australian markets soon with its dermatology, gastro and pain management products and gradually expand product portfolio.

Lincoln Pharma gets approval from Australian Regulator

Board of Lincoln Pharmaceuticals approves allotment of 29,728 equity shares

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Lincoln Pharmaceuticals Limited (LPL) is engaged in the business of manufacturing, marketing and distribution of pharmaceutical products.